Publications

Publishing & Design
Archive

Publications

APGOT-OV11
  • Leading group KGOG
  • Clinical Trial Study A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance
  • Final number of patients 124
  • Participating groups JGOG, GCGS
  • Closure 2024
  • Publication Int J Gynecol Cancer. 2024 Nov 4;34(11):1809-1812. doi: 10.1136/ijgc-2024-005838.
APGOT-OV10
  • Leading group GOG
  • Clinical Trial Study A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
  • Final number of patients 360
  • Participating groups Korea, ANZGOG
  • Closure 2025
  • Publication Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2.
APGOT-OV7
  • Leading group Korea
  • Clinical Trial Study A three-arm randomized phase II study of Dostarlimab alone or with Bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma
  • Final number of patients 198
  • Participating groups TGOG, HK, GOTIC, GCGS, ANZGOG, GTG-UK (ENGOT)
  • Closure 2025
  • Publication J Gynecol Oncol. 2025 Jan;36(1):e51. doi: 10.3802/jgo.2025.36.e51. Epub 2024 Dec 16.
APGOT-OV4
  • Leading group Korea
  • Clinical Trial Study A single-arm phase II study of Olaparib maintenance with Pembrolizumab & Bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer
  • Final number of patients 44
  • Participating groups GCGS
  • Closure 2023
  • Publication J Gynecol Oncol. 2021 Mar;32(2):e31. doi: 10.3802/jgo.2021.32.e31. Epub 2021 Jan 27.
    Nat Commun. 2023 Sep 6;14(1):5476. doi: 10.1038/s41467-023-40829-2